There is no cure for multiple sclerosis (MS); however, a number of strategies exist for disease management, including medications that reduce the frequency of relapses and long-term accrual of disability. 1 However, the fact that MS therapies can be partially effective and have the risk of side effects, in addition to the observation that disability often continues to worsen despite immunotherapy, has highlighted the need for novel therapeutic targets in the disease.
Heterotrimeric G proteins mediate a diverse array of physiological responses to extracellular stimuli (neurotransmitters, chemokines, hormones and environmental stimuli) received by G proteincoupled receptors (GPCRs). 2 GPCRs are important drug targets in human disease, 3 and more importantly, dysfunction of genes encoding G proteins is linked to certain diseases in humans, including inflammation, cancer and neurological disorders. 4 In particular, considerable evidence indicates that GPCRs mediate key processes underpinning the development of MS and experimental autoimmune encephalomyelitis (EAE), including blood − brain barrier permeability, T-cell activation, antigen presentation and glial reactivity. 3 Indeed, fingolimod (Gilenya, Novartis, Switzerland), the currently available immunomodulatory therapy for MS, targets the sphingosine-1 phosphate (S1P) receptor, a ubiquitous GPCR. 5 Activation of this GPCR results in the prevention of lymphocyte egress from lymph nodes, 6 thus reducing infiltration into the central nervous system and immune-mediated cellular damage in MS.
Heterotrimeric G proteins consist of α-, β-and γ-subunits, with the α-subunit having the proclivity to interact with the GPCR. The G protein α-subunits are classified into five major families, Gαq, Gαi, Gαs, Gα12 and Gαv, with subsequent subdivisions characterized. 7 A large proportion of GPCRs rely on Gαq, making this family a broad player in the regulation of physiological functions. With relevance to disease, blocking Gαq ameliorates murine lupus, 8 with overexpression of Gαq linked to pancreatitis, 9 indicating a role for Gαq signaling in disease pathogenesis. In support of this, Gαq is a well-characterized player in the mechanisms driving MS, including the regulation of T-cell survival 10 and migration, 11 and a body of data indicates that targeting Gαq-coupled signaling may by a therapeutic avenue in MS. 12, 13 In the present issue of Cellular and Molecular Immunology, Lai et al. 14 targeted this link between Gαq signaling and MS using Gαq knockout animals in the EAE model. The results of these experiments were clear-cut. The authors firstly determined the neuroimmune expression profile of the Gαq subunit during EAE development, targeting lymph nodes, the spleen, the cerebrum and the lumbar spinal cord. Gαq was abundant throughout these tissues, and was moderately enhanced in lymph nodes during EAE development. The role of Gαq in EAE was conclusive, as the development of EAE pathogenesis (enhanced clinical score, CNS leukocyte infiltration, demyelination, GFAP reactive gliosis, axonal damage in the spine) was markedly reduced in Gαq knockout animals.
Lai et al. 14 also present comprehensive evidence that the development of Th17 cells in vivo was blunted during EAE development in mice deficient for Gαq. 14 Indeed, these animals demonstrate reduced percentages of Th17 cells in CD4 + populations in lymph nodes from EAE mice. Furthermore, MOG 35-55 re-stimulation of lymph node leukocytes indicated the interleukin (IL)-17A-and Th17-associated genes (IL23R, IL-22) were ameliorated in Gαq-knockout EAE mice. A further set of in vitro experiments indicated that the differentiation of Th17 cells was inhibited in CD4 + T cells from Gαq-deficient mice, with data indicating that Gαq deletion reduces IL-17A secretion from Th17-polarized CD4 + T cells.
In a final set of experiments, the authors targeted the role of Gαq in IL-6 production by bone marrow-derived dendritic cells (BMDCs), with a view to determining the influence of Gαq on Th17 differentiation indirectly by modulating IL-6 production by BMDCs. 14 Inhibitor experiments indicated that Gαq signaling via phospholipase C-β, protein kinase C and mitogen-activated protein kinases mediated IL-6 secretion by dendritic cells (DCs). A number of intricate experiments determined that IL-6 expression was reduced in the spleen and serum of Gαq knockout animals, and that IL-6 secretion was markedly reduced in lipopolysaccharide-stimulated (to induce DC maturation) BMDCs isolated from Gαq mice, compared to BMDCs from wild types. In vitro DC − T cell co-culture experiments confirmed that Gαq signaling in DCs is integral in regulating Th17 cell differentiation.
Taken together, the results in this paper demonstrate a pivotal role of Gαq in controlling the differentiation of Th17 cells, and subsequent development of EAE pathogenesis. The findings of Lai et al. 14 are novel and add incrementally to our understanding of the contribution of G proteins, specifically Gαq signaling, to the mechanisms driving the development of EAE. It remains to be seen, however, if these findings translate to human samples from patients with relapsing − remitting or progressive forms of the disease. However, the findings of Lai et al. 14 certainly place the spotlight on Gαq as the headline act to take to the stage in the development of new GPCR strategies for MS therapy.
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